MedTrace Logo

Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

NCT01932203 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2019-08-08

No results posted yet for this study

Summary

There may be a difference in efficacy of cilostazol and aspirin on progression of white matter changes in cerebral small vessel disease.

Conditions

  • Cerebral Small Vessel Disease

Interventions

DRUG

aspirin

100mg once a day

DRUG

cilostazol

200mg once a day

Sponsors & Collaborators

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    collaborator INDUSTRY

  • Inha University Hospital

    lead OTHER

Principal Investigators

  • Seong Hye Choi, MD, PhD · Inha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-17
Primary Completion
2019-08-06
Completion
2019-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01932203 on ClinicalTrials.gov